Answers are grounded in this paper and cite their sources.
Population-based study estimates HPV seroprevalence and associated factors in unvaccinated women, suggesting vaccination benefits.
OBJECTIVES: To estimate the seroprevalence of human papillomavirus (HPV) types included in the nonavalent HPV (9vHPV) vaccine among unvaccinated women and determine factors associated with seropositivity. METHODOLOGY: Data from a population-based cross-sectional study of HPV infection among sexually active women (16-64 years) conducted in Puerto Rico from 2010 to 2013 was assessed (n = 524). Antibody responses to 9vHPV types (HPV-6/11/16/18/31/33/45/52/58) were analyzed using M9ELISA by the United States Centers for Disease Control and Prevention. Age-adjusted prevalence odds ratios (aPOR) were estimated with 95% confidence intervals (CI). RESULTS: The mean participant age was 42.4 ± 0.6 years; 69.2% were seropositive to ≥1 of the 9vHPV types and 0.5% to all types. Women who had their sexual debut at ≥18 years old (aPOR: 0.4, 95% CI: 0.2-0.8) had lower odds of seropositivity to any 9vHPV types compared to those with a younger sexual debut age. Higher odds of seropositivity were observed among women with 3-9 (aPOR: 4.4, 95% CI: 1.9-10.2) and with ≥10 (aPOR: 4.3, 95% CI: 1.5-12.6) lifetime sexual partners, and women with a history of an abnormal Pap test result (aPOR: 2.5, 95% CI: 1.1-5.6) compared to their counterparts. CONCLUSION: The high seroprevalence of 9vHPV types found in our study underscores the potential benefits of following the recommended vaccine schedule to reduce HPV and cervical cancer burden in this population.
No takes yet. Share an insight, caveat, or question.
Cruz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: